SWI Adds Cellular Biomedicine Group to its WatchIndex

Los Angeles, March 12, 2015 — StockWatchIndex today has added Cellular Biomedicine Group (CBMG – NasdaqCM) to its WatchIndex on stockwatchindex.com. CBMG has had an absolute exceptional run since we initiated coverage in January of 2015. The stock is up from $18.00 on January 15, 2015 closing at $46.45 yesterday, March 11,2015; an increase of 158%. CBMG has a market cap of $462 Million. The Company has 9.95 Million shares outstanding with 7 Million in the float and an average volume of 100, 938 shares per day, steadily increasing over the last ten days. CBMG is lead by a exceptional management team and we believe that as the company’s basics keep improving for CBMG, so will the share price.

Cellular Biomedicine Group is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. CBMG is the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. The Company’s leading cellular research and development results from collaboration among scientists and doctors from the US, Europe and China. CBMG is partnering its programs at the stage of early to mid clinical development and the licensing of other applications after seeing them through the proof of concept stage.


Please try out our new service www.swiresearch.com. We would appreciate if you could please pass this on to your friends and colleagues and we always appreciate your feedback and comments. For detauiled information on Cellular Biomedicne Group go to www.cellbiomedgroup.com.

For an interview with Dr. Wei Cao, CEO & Director of Cellular Biomedicine Group go to Wide World of Stocks.  


 About SWI
SWI is a leading edge PR, Information Marketing and Research Service with a highly frequented web site www.stockwatchindex.com, its “Rise Above The Noise” newsletter and SWI Research site www.swiresearch.com. These services provide you with information and research on new and promising public companies. The QuickPicks section on the SWI site represent the consolidated opinions of carefully selected financial analyst blogs and opinions of Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on https://stockwatchindex.com/swi-quickpicks for more detail.  SWI’s periodical “Portfolio Performance Report” frequently updates on the performance of the stocks that we have purchased and are holding in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.  

 Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. We have contracted with some of the companies we present on SWI as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice